Back to Search
Start Over
Next-generation sequencing in patients with advanced cancer: are we ready for widespread clinical use? A single institute's experience
- Source :
- Anti-cancer drugs. 27(9)
- Publication Year :
- 2016
-
Abstract
- The next-generation sequencing (NGS) assay targeting cancer-relevant genes has been adopted widely for use in patients with advanced cancer. The primary aim of this study was to assess the clinical utility of commercially available NGS. We retrospectively collected demographic and clinicopathologic data, recommended therapy, and clinical outcomes of 30 patients with a variety of advanced solid tumors referred to Foundation Medicine NGS. The initial pathologic examination was performed at the pathology department of the referring hospital. The comprehensive clinical NSG assay was performed on paraffin-embedded tumor samples using the Clinical Laboratory Improvement Amendments-certified FoundationOne platform. The median number of genomic alterations was 3 (0-19). The median number of therapies with potential benefit was 2 (0-8). In 12 cases, a comprehensive clinical NGS assay did not indicate any therapy with potential benefit according to the genomic profile. Ten of the 30 patients received treatments recommended by genomic profile results. In six of the 10 cases, disease progressed within 2 months and four patients died within 3 months of treatment initiation. Three of the 30 patients benefited from a comprehensive clinical NGS assay and the subsequent recommended therapy. The median PFS was 12 weeks (95% confidence interval 10-57) in patients treated with molecularly targeted agents chosen on the basis of tumor genomic profiling versus 48 weeks (95% confidence interval 8-38) in the control group treated with physician choice therapy (P=0.12). Our study suggests that NGS can detect additional treatment targets in individual patients, but prospective medical research and appropriate clinical guidelines for proper clinical use are vital.
- Subjects :
- Adult
Male
Cancer Research
Pathology
medicine.medical_specialty
Genomic profiling
Disease
DNA sequencing
Disease-Free Survival
03 medical and health sciences
Young Adult
0302 clinical medicine
Treatment targets
Internal medicine
Neoplasms
medicine
Humans
Pharmacology (medical)
In patient
030212 general & internal medicine
Aged
Pharmacology
Aged, 80 and over
Paraffin Embedding
business.industry
High-Throughput Nucleotide Sequencing
Middle Aged
Advanced cancer
Confidence interval
Oncology
030220 oncology & carcinogenesis
Genomic Profile
Female
business
Subjects
Details
- ISSN :
- 14735741
- Volume :
- 27
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- Anti-cancer drugs
- Accession number :
- edsair.doi.dedup.....c8a72f4f35be83a890bd7061df25edf8